LLY's Onswik Wins FDA Nod as a Once-Weekly Basal Insulin for T2D

Eli Lilly and Company LLY secured FDA approval for Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin to treat adults with type II diabetes (T2D). It is approved for use along with diet and exercise to help control blood sugar levels. Onswik is designed to provide steady basal insulin levels for seven days, allowing patients to replace daily injections with a once-weekly option. Per the company, the drug could provide greater flexibility and convenience for adults with T2D who require insulin treatment. Onswik is not approved for people with type I diabetes, as its use in this population may increase the risk of severe hypoglycemia (low blood sugar). The U.S.